We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Prime Medicine, Inc. achieved strong early data in CGD with PM359, surpassing efficacy thresholds. Click here to find out why ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, ...

Prime Medicine (NASDAQ:PRME) stock rose 32%, extending recent gains following Eli Lilly’s (NYSE:LLY) acquisition deal for Verve Therapeutics (NASDAQ:VERV) last month.

Eli Lilly LLY -0.47% agreed to acquire Verve Therapeutics VERV 0.45% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic ...

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk Provided by PR Newswire Jun 17, 2025, 10:45:00 AM ...